| Product | Target | Load | Indication | Development Phase |
|
Pre-clin Phase I Phase I/II Phase II Phase III |
||||
| Burtomab | B7-H3 | 131l | CNS/Leptomeningeal Metastasis from Neuroblastoma (BTD, ODD and RPDD) |
|
| Burtomab | B7-H3 | 131l | Desmoplastic Small Round Cell Tumor |
|
| Burtomab | B7-H3 | 124l | Diffuse Intrinsic Pontine Glioma (RPDD) |
|
| Burtomab-DOTA | B7-H3 | 177Lu | B7-H3 positive LM tumors (Adult) |
|
| hu8H9 | B7-H3 | TBD | Solid Tumors (Adult) |
|
| Naxitamab | GD2 | Naked | Refractory/Relapsed Neuroblastoma (ODD) |
|
| Naxitamab | GD2 | Naked | Osteosarcoma (Pediatric) (ODD) |
|
| hu3F8-BsAb | GD2xCD3 | Naked | GD2 positive solid tumors (Adult) |
|
| hu3F8-BsAb | GD2xCD3 | Naked | Refractory Neuroblastoma and Ewing's Sarcoma (Pediatric) |
|
BTD (Breakthrough Therapy Designation), ODD (Orphan Drug Designation) and RPDD (Rare Pediatric Disease Designation)
Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.
YmAbs mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.
